What Taysha Gene Therapies, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 12 |
| Total trades | 0 | 25 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 2,468,533 |
| Disposed | 0 | 1,368,795 |
| Net activity | +0 | +1,099,738 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Nagendran Sukumar | President and Head of R&D | Jul 10 | Open-market sale · S | −200,000 | $6.24 | −$1.25M | 936,410 |
| Donenberg Philip B | Director | Jun 01 | Grant / award · A | +21,335 | — | — | 241,289 |
| Stalfort Sean | Director | Jun 01 | Grant / award · A | +21,335 | — | — | 1,176,559 |
| Sepp-Lorenzino Laura | Director | Jun 01 | Grant / award · A | +21,335 | — | — | 127,178 |
| Long Alison S | Director | Jun 01 | Grant / award · A | +21,335 | — | — | 127,178 |
| Nagendran Sukumar | President and Head of R&D | Apr 10 | Open-market sale · S | −200,000 | $4.46 | −$892K | 1,136,410 |
| Nagendran Sukumar | President and Head of R&D | Apr 10 | Exercise / conversion · M | +19,021 | $1.71 | +$32.5K | 1,336,410 |
| Alam Kamran | CHIEF FINANCIAL OFFICER | Feb 04 | Sale for tax withholding · S | −1,655 | $4.52 | −$7.48K | 1,442,131 |
| Alam Kamran | CHIEF FINANCIAL OFFICER | Jan 26 | Sale for tax withholding · S | −23,849 | $4.61 | −$110K | 1,443,786 |
| Nolan Sean P. | Chief Executive Officer | Jan 26 | Sale for tax withholding · S | −41,312 | $4.61 | −$190K | 2,908,257 |
| Nagendran Sukumar | President and Head of R&D | Jan 26 | Sale for tax withholding · S | −26,918 | $4.61 | −$124K | 1,317,389 |
| Alam Kamran | CHIEF FINANCIAL OFFICER | Jan 23 | Sale for tax withholding · S | −78,968 | $4.75 | −$375K | 1,467,635 |
| Nolan Sean P. | Chief Executive Officer | Jan 23 | Sale for tax withholding · S | −136,789 | $4.75 | −$650K | 2,949,569 |
| Nagendran Sukumar | President and Head of R&D | Jan 23 | Sale for tax withholding · S | −89,132 | $4.75 | −$423K | 1,344,307 |
| Alam Kamran | CHIEF FINANCIAL OFFICER | Jan 12 | Grant / award · A | +359,000 | — | — | 1,546,603 |
| Nolan Sean P. | Chief Executive Officer | Jan 12 | Grant / award · A | +1,008,000 | — | — | 3,086,358 |
| Nagendran Sukumar | President and Head of R&D | Jan 12 | Grant / award · A | +427,000 | — | — | 1,433,439 |
| Nagendran Sukumar | President and Head of R&D | Jan 12 | Open-market sale · S | −200,000 | $4.71 | −$942K | 1,006,439 |
| Nagendran Sukumar | President and Head of R&D | Jan 12 | Exercise / conversion · M | +88,676 | $1.71 | +$152K | 1,206,439 |
| Nagendran Sukumar | President and Head of R&D | Jan 12 | Exercise / conversion · M | +111,324 | $0.70 | +$77.8K | 1,117,763 |
Loading...
